3-Methylglutaric acid (MGA, 3MG acid) is a conspicuous C6 dicarboxylic organic acid that can be used as a single solid-state NMR standard compound to perform all calibration steps except for magnet shimming.
research use only
Cat.No.S3347
|
In vitro |
DMSO
: 29 mg/mL
(198.43 mM)
Water : 29 mg/mL Ethanol : 29 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 146.14 | Formula | C6H10O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 626-51-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | MGA, 3MG acid | Smiles | CC(CC(O)=O)CC(O)=O | ||
| References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04116073 | Recruiting | Pancreatic Cancer Non-resectable|Pancreatic Cancer Metastatic |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Incyte Corporation|National Cancer Institute (NCI) |
April 9 2020 | Phase 2 |
| NCT04158726 | Completed | Acute Myeloid Leukemia |
Carevive Systems Inc. |
April 26 2019 | Not Applicable |
| NCT02923180 | Active not recruiting | Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|MacroGenics |
February 14 2017 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.